Literature DB >> 27629435

The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.

Romina Fiorotto1,2, Ambra Villani1, Antonis Kourtidis3, Roberto Scirpo1, Mariangela Amenduni1, Peter J Geibel4, Massimiliano Cadamuro2,5, Carlo Spirli1,2, Panos Z Anastasiadis3, Mario Strazzabosco1,2,5.   

Abstract

In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice).
CONCLUSION: These findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27629435      PMCID: PMC5115965          DOI: 10.1002/hep.28817

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

1.  Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration.

Authors:  Fanyin Meng; Heather Francis; Shannon Glaser; Yuyan Han; Sharon DeMorrow; Allison Stokes; Dustin Staloch; Julie Venter; Melanie White; Yoshiyuki Ueno; Lola M Reid; Gianfranco Alpini
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

2.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

4.  Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice.

Authors:  Ryo Hatano; Kaori Akiyama; Atsushi Tamura; Shigekuni Hosogi; Yoshinori Marunaka; Michael J Caplan; Yoshiyuki Ueno; Sachiko Tsukita; Shinji Asano
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases.

Authors:  M Kawabuchi; Y Satomi; T Takao; Y Shimonishi; S Nada; K Nagai; A Tarakhovsky; M Okada
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

6.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation.

Authors:  Laura Fouassier; Peter Rosenberg; Martine Mergey; Bruno Saubaméa; Audrey Clapéron; Nils Kinnman; Nicolas Chignard; Gunilla Jacobsson-Ekman; Birgitta Strandvik; Colette Rey; Véronique Barbu; Rolf Hultcrantz; Chantal Housset
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

8.  Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance.

Authors:  Andrei E Medvedev; Wenji Piao; Joanna Shoenfelt; Sang Hoon Rhee; Haiyan Chen; Subhendu Basu; Larry M Wahl; Matthew J Fenton; Stefanie N Vogel
Journal:  J Biol Chem       Date:  2007-03-28       Impact factor: 5.157

9.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.

Authors:  Gerrit John; Ali O Yildirim; Bruce K Rubin; Dieter C Gruenert; Markus O Henke
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

10.  A mouse model for the delta F508 allele of cystic fibrosis.

Authors:  B G Zeiher; E Eichwald; J Zabner; J J Smith; A P Puga; P B McCray; M R Capecchi; M J Welsh; K R Thomas
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  27 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 2.  Emerging concepts in biliary repair and fibrosis.

Authors:  Luca Fabris; Carlo Spirli; Massimiliano Cadamuro; Romina Fiorotto; Mario Strazzabosco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

Review 3.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

Review 4.  Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Authors:  Mario Strazzabosco; Romina Fiorotto; Massimiliano Cadamuro; Carlo Spirli; Valeria Mariotti; Eleanna Kaffe; Roberto Scirpo; Luca Fabris
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-25       Impact factor: 5.187

5.  β-Catenin and interleukin-1β-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis.

Authors:  Eleanna Kaffe; Romina Fiorotto; Francesca Pellegrino; Valeria Mariotti; Mariangela Amenduni; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco; Carlo Spirli
Journal:  Hepatology       Date:  2018-03-25       Impact factor: 17.425

Review 6.  Animal models of biliary injury and altered bile acid metabolism.

Authors:  Valeria Mariotti; Mario Strazzabosco; Luca Fabris; Diego F Calvisi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-11       Impact factor: 5.187

7.  Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

Review 8.  Liver disease in patients with cystic fibrosis.

Authors:  Natasha Kamal; Pallavi Surana; Christopher Koh
Journal:  Curr Opin Gastroenterol       Date:  2018-05       Impact factor: 3.287

Review 9.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

Review 10.  Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer.

Authors:  Jieting Zhang; Yan Wang; Xiaohua Jiang; Hsiao Chang Chan
Journal:  Cell Mol Life Sci       Date:  2018-02-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.